Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5926)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 7, 2023 (publication date) through Feb 14, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Villarruel-Melquiades F, Mendoza-Garrido ME, García-Cuellar CM, Sánchez-Pérez Y, Pérez-Carreón JI, Camacho J. Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma. World J Gastroenterol 2023; 29(17): 2571-2599 [PMID: PMC10198058 DOI: 10.3748/wjg.v29.i17.2571] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i17/2571.htm |
| Number | Citing Articles |
| 1 |
Niyaz Malayev, Samat Saparbayev, Saule Kubekova, Nurlan Zhampeissov. Actual issues of secondary prevention of liver cancer in Kazakhstan. Journal of Clinical Medicine of Kazakhstan 2023; 20(6): 66 doi: 10.23950/jcmk/13926
|
| 2 |
Jun-Tao Li, Hong-Mei Zhang, Wei Wang, Dong-Qing Wei. Identification of an immune-related gene signature for predicting prognosis and immunotherapy efficacy in liver cancer <i>via</i> cell-cell communication. World Journal of Gastroenterology 2024; 30(11): 1609-1620 doi: 10.3748/wjg.v30.i11.1609
|
| 3 |
D.K. Sabir, J.A. Bin Jumah, I. Ancy. Unveiling key drivers of hepatocellular carcinoma: a synergistic approach with network pharmacology, machine learning-driven ligand discovery and dynamic simulations. SAR and QSAR in Environmental Research 2024; 35(11): 1045 doi: 10.1080/1062936X.2024.2434577
|
| 4 |
Noha S. Basuony, Tarek M. Mohamed, Doha M. Beltagy, Ahmed A. Massoud, Mona M. Elwan. Therapeutic Effects of Crocin Nanoparticles Alone or in Combination with Doxorubicin against Hepatocellular Carcinoma In vitro. Anti-Cancer Agents in Medicinal Chemistry 2025; 25(3): 194 doi: 10.2174/0118715206327654240823074318
|
| 5 |
Varshni Premnath, Shanthi Veerappapillai. Unveiling miRNA–Gene Regulatory Axes as Promising Biomarkers for Liver Cirrhosis and Hepatocellular Carcinoma. ACS Omega 2024; 9(44): 44507 doi: 10.1021/acsomega.4c06551
|
| 6 |
Kazunori Sato, Kouichi Miura, Hiroaki Nomoto, Shunji Watanabe, Hiroshi Maeda, Rie Goka, Mamiko Tsukui, Naoko Saito, Momoe Sakurai, Akihito Takei, Shun Ishibashi, Naoya Yahagi, Naoki Morimoto, Hironori Yamamoto. Case of hepatocellular carcinoma with adrenocortical insufficiency following combination treatment of atezolizumab and bevacizumab. Kanzo 2024; 65(5): 231 doi: 10.2957/kanzo.65.231
|
| 7 |
Qinjuan Wu, Xin Li, Menghong Long, Xianfeng Xie, Qing Liu. Integrated analysis of histone lysine lactylation (Kla)-specific genes suggests that NR6A1, OSBP2 and UNC119B are novel therapeutic targets for hepatocellular carcinoma. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-46057-4
|
| 8 |
Srijita Sen, Hemant Kushwah, Om Prakash Ranjan. Drug Repurposing. 2024; : 57 doi: 10.1007/978-981-97-5016-0_5
|
| 9 |
Xinyu Gu, Shuang Li, Xiao Ma, Di Huang, Penghui Li. Heterogeneity characterization of hepatocellular carcinoma based on the sensitivity to 5-fluorouracil and development of a prognostic regression model. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1252805
|
| 10 |
Zengbin Wang, Linqing Wu, Yu Zhou, Zhong Chen, Tao Zhang, Hong Wei, Zhihong Wang. Protein and metabolic profiles of tyrosine kinase inhibitors co-resistant liver cancer cells. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1394241
|
| 11 |
Chun-yan Feng, Cheng-song Cai, Xiao-qian Shi, Zhi-juan Zhang, Dan Su, Yun-qing Qiu. Resveratrol promotes mitophagy via the MALAT1/miR-143-3p/RRM2 axis and suppresses cancer progression in hepatocellular carcinoma. Journal of Integrative Medicine 2025; 23(1): 79 doi: 10.1016/j.joim.2024.11.003
|
| 12 |
Nora A. Mohamad, Tamara E. Galarza, Gabriela A. Martín. H2 antihistamines: May be useful for combination therapies in cancer?. Biochemical Pharmacology 2024; 223: 116164 doi: 10.1016/j.bcp.2024.116164
|
| 13 |
Min Wei, Pengwei Zhang, Chaofeng Yang, Yang Li. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1500496
|